术前检测癌相关血清抗原（CASA）和CA-125以鉴别盆腔良恶性肿瘤肿块：一项前瞻性研究。

Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.

作者信息

Sehouli Jalid, Akdogan Zera, Heinze Thomas, Könsgen Dominique, Stengel Dirk, Mustea Alexander, Lichtenegger Werner

机构信息

Charité, Department of Obstetrics and Gynaecology, Humboldt University, Augustenburger Platz 1, D-13353 Berlin, Germany.

出版信息

Anticancer Res. 2003 Mar-Apr;23(2A):1115-8.

PMID:12820357

Abstract

BACKGROUND

CA-125 is the most important tumor marker in epithelial ovarian cancer. Due to its low specificity, a combination with CASA may improve the clinical discrimination between benign and malignant adnexal masses.

MATERIALS AND METHODS

In a prospective study CA-125 and CASA were analyzed in blood specimens of 153 patients, including 29 ovarian cancer.

RESULTS

The median levels of both markers were significantly higher in ovarian cancer than in benign diseases. The sensitivity of CA-125 was 90%, while the specificity was 79%. PPV and NPV were 50% and 97%. In comparison, the sensitivity of CASA was lower (38%), while the specificity was slightly higher (86%). PPV and NPV were 39% and 86%. When both markers were used together, the specificity could be increased to 96% but the sensitivity remained at only 38%. The PPV and NPV was 69% and 87%.

CONCLUSION

The combination of CA-125 and CASA can improve the detection of patients with suspected ovarian cancer.

摘要

背景

CA - 125是上皮性卵巢癌中最重要的肿瘤标志物。由于其特异性较低，与CASA联合使用可能会提高对附件包块良恶性的临床鉴别能力。

材料与方法

在一项前瞻性研究中，对153例患者的血液样本进行了CA - 125和CASA分析，其中包括29例卵巢癌患者。

结果

两种标志物的中位数水平在卵巢癌患者中均显著高于良性疾病患者。CA - 125的敏感性为90%，特异性为79%。阳性预测值和阴性预测值分别为50%和97%。相比之下，CASA的敏感性较低（38%），而特异性略高（86%）。阳性预测值和阴性预测值分别为39%和86%。当两种标志物联合使用时，特异性可提高到96%，但敏感性仅为38%。阳性预测值和阴性预测值分别为69%和87%。